GlaxoSmithKline says laboratory analysis of the antibody-based COVID -19 therapy it is developing with U.S. partner Vir has indicated the drug is effective against the new Omicron variant
Laboratory analysis of the antibody-based COVID -19 therapy GlaxoSmithKline (GSK) is developing with U.S. partner Vir has indicated the drug is effective against the new Omicron variant, the British drugmaker said on Thursday.
has indicated the drug is effective against the new Omicron variant, the British drugmaker said on Thursday.A GSK statement said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail works against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant.
The two companies have been engineering so-called pseudoviruses that feature major coronavirus mutations across all suspicious variants that have emerged so far, and have run lab tests on their vulnerability to sotrovimab treatment.Register now for FREE unlimited access to reuters.com
RegisterAn analysis of past tests has now yielded the preliminary clearance for the drug, because Omicron' main mutations have been found across a variety of previous variants."We've been carefully following every mutation that might be important," said Herbert Virgin, Vir's Chief Scientific Officer. headtopics.com
"With this new variant, the mutations that we have tested so far have no significant effect on sotrovimab," he added.Importantly, the mutations within the area on the spike protein that the sotrovimab antibodies bind to did not make a difference.
For confirmation, a pseudovirus with all of the Omicron mutations is now being tested, with an update expected by the end of the year, GSK added in its statement.The antibody is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.
“Sotrovimab was deliberately designed with a mutating virus in mind," said Vir Chief Executive George Scangos, adding that the drug was targeting a region of the spike protein that was highly unlikely to mutate.Separately, Britain's drug regulator on Thursday approved sotrovimab, also known under the brand name Xevudy, for people with mild to moderate COVID-19 and who are at high risk of developing severe disease.
The Medicines and Healthcare products Regulatory Agency (MHRA) recommended use of Xevudy as soon as possible and within five days of the onset of symptoms.Read more: Reuters Top News »
Video: 'Once in a lifetime' rare blanket octopus spotted in Australia - CNN Video
The rainbow-hued octopus, seen swimming on the Great Barrier Reef, was caught on video by marine biologist Jacinta Shackleton.
UK Approves Covid Antibody Treatment That's Likely Effective Against Omicron—Here's What To KnowI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com The Global Elite Intend To Reduce The World's Population By 90 Percent To Below 500 Million By Engineering Pandemics In the Laboratory And Unleashing Them Upon the World To Depopulate The planet
Glaxo’s Covid-19 Antibody Drug Found to Be Effective Against OmicronThe antibody treatment was effective against the variant in early laboratory studies, setting it apart from similar therapies that appear to work less well against the highly mutated strain. US Gov. NIH website 2011: 'IVERMECTIN ... immeasurable beneficial impact in improving the lives of BILLIONS of PEOPLE - being used FREE of charge ... 'wonder drug'' Can we have NEW *EUA* drugs - to ultimately market ... if there's an existing treatment? Supported by the Bill & Melinda Gates Foundation. Billy has his fingers in the pie everywere.
Omicron: India reports first cases of new Covid variantTwo travellers who landed in India's Bangalore city tested positive for the Omicron variant.
Moderna Warns of ‘Material Drop’ in Vaccine Efficacy Against OmicronThe Moderna CEO says existing COVID -19 vaccines will likely be less effective against the new Omicron variant. “I think it’s going to be a material drop,” he said. “I just don’t know how much, because we need to wait for the data.'
this is terrible news Oh well. Just come in thru the Southern border unchecked and un taxed and wait for your $450,000 check.
Do Current COVID-19 Tests Still Detect Omicron?Here’s how the current COVID -19 tests, whether they’re done by a lab or at-home, work against the latest variant At least they can't blame the unvaccinbated as the ones bringing it are travellers and the unvaccinated can't travel , only those vaccinated can with passports need to focus on immutable sites to kill the virus and avoid variants. Enzc already done it and they have the cure